for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vericel Corp

VCEL.OQ

Latest Trade

15.45USD

Change

-0.05(-0.32%)

Volume

85,511

Today's Range

15.36

 - 

15.66

52 Week Range

10.51

 - 

21.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Vericel Reports Second Quarter 2019 Financial Results And Raises Full Year 2019 Revenue Guidance

Aug 6 (Reuters) - Vericel Corp <VCEL.O>::VERICEL REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RAISES FULL YEAR 2019 REVENUE GUIDANCE.Q2 LOSS PER SHARE $0.45.Q2 EARNINGS PER SHARE ESTIMATE $-0.47 -- REFINITIV IBES DATA.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.05 EXCLUDING ITEMS.SEES FY 2019 REVENUE $112 MILLION TO $116 MILLION.FY2019 REVENUE VIEW $113.2 MILLION -- REFINITIV IBES DATA.

Vericel Q1 Loss Per Share $0.07

Vericel Corp <VCEL.O>::VERICEL REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RAISES FULL YEAR 2019 REVENUE GUIDANCE.Q1 LOSS PER SHARE $0.07.Q1 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.QTRLY TOTAL NET PRODUCT REVENUES INCREASED 21% TO $21.8 MILLION COMPARED TO $18.0 MILLION IN Q1 OF 2018.QTRLY GROSS MARGINS OF 60% COMPARED TO GROSS MARGINS OF 57% IN Q1 OF 2018.NOW EXPECTS TOTAL MACI AND EPICEL NET PRODUCT REVENUES FOR FULL YEAR 2019 TO BE IN RANGE OF $110 TO $114 MILLION.Q1 REVENUE VIEW $22.5 MILLION -- REFINITIV IBES DATA.

Vericel Has Entered Into Exclusive License And Supply Agreements With Mediwound To Commercialize Nexobrid® In North America

May 7 (Reuters) - Vericel Corp <VCEL.O>::HAS ENTERED INTO EXCLUSIVE LICENSE AND SUPPLY AGREEMENTS WITH MEDIWOUND TO COMMERCIALIZE NEXOBRID® IN NORTH AMERICA.PIVOTAL U.S. PHASE 3 CLINICAL STUDY MET PRIMARY AND ALL SECONDARY ENDPOINTS.VERICEL -UNDER TERMS, VERICEL WILL MAKE UPFRONT PAYMENT TO MEDIWOUND OF $17.5 MILLION, WITH AN ADDITIONAL $7.5 MILLION PAYMENT CONTINGENT UPON U.S. APPROVAL.VERICEL - UNDER THE TERMS OF THE LICENSE AGREEMENT, VERICEL WILL PAY MEDIWOUND UP TO $125 MILLION CONTINGENT UPON MEETING CERTAIN ANNUAL SALES MILESTONES.VERICEL-ENTERED AGREEMENT WITH MEDIWOUND, WHERE MEDIWOUND WILL MANUFACTURE NEXOBRID FOR VERICEL FOR A SUPPLY PRICE OF COST PLUS FIXED MARGIN PERCENTAGE.

Vericel Q4 Earnings Per Share $0.11

Feb 26 (Reuters) - Vericel Corp <VCEL.O>::VERICEL REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES FULL-YEAR 2019 FINANCIAL GUIDANCE.Q4 EARNINGS PER SHARE $0.11.Q4 EARNINGS PER SHARE ESTIMATE $0.04 -- REFINITIV IBES DATA.QTRLY GROSS MARGINS OF 72% COMPARED TO GROSS MARGINS OF 64% IN Q4 OF 2017.EXPECTS TOTAL NET PRODUCT REVENUES FOR 2019 TO BE IN RANGE OF $108 MILLION TO $112 MILLION..EXPECTS MARGINS TO CONTINUE TO INCREASE IN 2019.TOTAL NET PRODUCT REVENUES FOR QUARTER ENDED DECEMBER 31, 2018 INCREASED 41% TO $31.3 MILLION COMPARED TO $22.2 MILLION IN Q4 OF 2017.Q4 REVENUE VIEW $28.7 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $109.9 MILLION -- REFINITIV IBES DATA.

James Flynn Reports 6.15 Pct Passive Stake In Vericel Corp As Of October 10

Oct 22 (Reuters) - Vericel Corp <VCEL.O>::JAMES FLYNN REPORTS 6.15 PERCENT PASSIVE STAKE IN VERICEL CORP AS OF OCTOBER 10 - SEC FILING.

Vericel Corp Files For Mixed Shelf Of Up To $200 Million

Aug 16 (Reuters) - Vericel Corp <VCEL.O>::VERICEL CORP FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.

Vericel Reports Second Quarter Revenue Of $19 Million

Aug 6 (Reuters) - Vericel Corp <VCEL.O>::VERICEL REPORTS RECORD SECOND QUARTER REVENUES OF $19.0 MILLION AND RAISES FULL YEAR 2018 REVENUE GUIDANCE.Q2 LOSS PER SHARE $0.12.Q2 REVENUE $19 MILLION VERSUS I/B/E/S VIEW $18.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $80 MILLION TO $83 MILLION.FY2018 REVENUE VIEW $78.1 MILLION -- THOMSON REUTERS I/B/E/S.

Vericel Says Amended Agreement With Orsini To Eliminate Orsini's Right To Serve As Exclusive Distributor For MACI

July 31 (Reuters) - Vericel Corp <VCEL.O>::VERICEL CORP SAYS AMENDED DISTRIBUTION AGREEMENT, DATED MAY 15, 2017 BETWEEN ORSINI PHARMACEUTICAL SERVICES AND CO - SEC FILING.VERICEL CORP - UNDER FOURTH AMENDMENT TO AGREEMENT, PARTIES AGREED TO ELIMINATE ORSINI'S RIGHT TO SERVE AS CO'S EXCLUSIVE DISTRIBUTOR FOR MACI.

Vericel Corporation Prices $65 Mln Public Offering Of Common Stock

May 31 (Reuters) - Vericel Corp <VCEL.O>::ORATION PRICES $65 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.00 MILLION COMMON SHARES PRICED AT $13.00PER SHARE.

Vericel Corporation Announces Proposed Public Offering Of Common Stock

May 30 (Reuters) - Vericel Corp <VCEL.O>::VERICEL CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.VERICEL CORP - INTENDS TO OFFER 3.75 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up